ClinicalTrials.gg
RecruitingNCT03821636PRECI-SurgUpdated Dec 23, 2025

Impact of Long Alimentary Limb or Long Biliary Limb Roux-en-Y Gastric Bypass on Type 2 Diabetes Remission in Severely Obese Patients.

An interventional study of Standard Roux-en-Y gastric bypass and Long alimentary limb Roux-en-Y gastric bypass in Diabetes Mellitus Type 2 in Obese, sponsored by University Hospital, Lille. Recruiting at 4 sites in France. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2025-12-23.

Sponsored by University Hospital, Lille · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2026, 5 months ago, but the record still lists the study as recruiting.
  • Started Jun 2019; still recruiting 7 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
396
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 23 studies in Obesity by University Hospital, Lille — 5 open to participants now, 7 under way, none of them phase 3. Obesity · University Hospital, Lille.

Started
2019
with 1 other
No phase
7 of 23
2 open now
Registered
16th of 23
by date

Among the 23 studies in Obesity by University Hospital, Lille, this one is one of 2 that started in 2019, is one of 7 with no phase, and was the 16th registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

5 of the 23 studies in Obesity by University Hospital, Lille are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Obesity by University Hospital, Lille, or all of them as a file.
02

Study summary

In patients with type 2 diabetes, Roux-en-Y gastric bypass (RYGB), which excludes a portion of the stomach and the proximal intestine from the alimentary circuit, improves glucose metabolism more rapidly and more extensively than is expected from weight loss. The mechanisms of this unique effect of gastrointestinal exclusion appear to be complex and have not yet been clarified. A recent study unveil that intestinal uptake of ingested glucose is diminished by RYGB and restricted to the common limb, where food meets bile and other digestive fluids, resulting in an overall decrease of post prandial blood glucose excursion. the hypothesize that reducing the length of the common limb, which is rarely measured and highly variable in clinical practice, may significantly affect the metabolic outcome of gastrointestinal surgical procedures. The aim of the present study is to compare the impact of two variants of Roux-en-Y gastric bypass with a short common limb, the long alimentary limb or the long biliary limb Roux-en-Y gastric bypass, on type 2 diabetes remission in severely obese patients.

03

Conditions studied

  • Diabetes Mellitus Type 2 in Obese

Keywords

  • Obesity
  • Diabetes Mellitus Type 2
  • Bariatric Surgery
  • Roux-en-Y
  • gastric bypass
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ≥ 35 kg/m2
  • All patient with type 2 diabetes
  • Patients who were candidates for obesity surgery in accordance with French recommendation

Exclusion criteria

Exclusion Criteria:

  • Severe cognitive or mental disorders
  • patient who have already undergone obesity surgery
  • Severe and non-stabilised eating disorders
  • The likely inability of the patient to participate in lifelong medical follow-up
  • Alcohol or psychoactive substances dependence
  • The absence of identified prior medical management of obesity
  • Diseases that are life-threatening in the short and medium term;
  • to general anaesthesia.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
396 participants (estimated)

Study arms

  • Sham comparator
    Standard Roux-en-Y

    Procedure: Standard Roux-en-Y gastric bypass

  • Active comparator
    Long alimentary limb Roux-en-Y

    Procedure: Long alimentary limb Roux-en-Y gastric bypass

Interventions

  • ProcedureStandard Roux-en-Y gastric bypass

    Standard Roux-en-Y gastric bypass is performed with a 30 ml gastric pouch, a stapled gastrojejunal anastomosis with an alimentary limb of 25 % of total length of the intestine (150 cm), connected to the biliary limb of 10 % of total length of the intestine (60 cm) below the duodeno-jejunal junction with a side-to-side jejuno-jejunal anastomosis and a common limb of 65 % of total length of the intestine (400 cm).

  • ProcedureLong alimentary limb Roux-en-Y gastric bypass

    Long alimentary limb Roux-en-Y gastric bypass is performed with a 30 ml gastric pouch, a stapled gastrojejunal anastomosis with an alimentary limb of 45 % of total length of the intestine (280 cm), connected to the biliary limb of 10 % of total length of the intestine (60 cm) below the duodeno-jejunal junction with a side-to-side jejuno-jejunal anastomosis and a common limb of 45 % of total length of the intestine (280 cm

06

What researchers measure

Primary outcomes

  1. Rate of type 2 diabetes remission

    HbA1c \< 6.5% AND fasting blood glucose \< 7.0 mmol/L in absence of antidiabetic drug

    Time frame: at 12 months after surgery

Secondary outcomes

  1. Absolute weight loss (aWL in kg)

    Time frame: at 1, 3, 6 and 12 months after surgery

  2. Excess Weight Loss percentage (EWL%)

    Time frame: at 1, 3, 6 and 12 months after surgery

  3. Excess BMI Loss percentage (EBL%)

    Time frame: at 1, 3, 6 and 12 months after surgery

  4. Medical and surgical complication rates

    Medical and surgical complication rates (anastomotic leaks, biliary reflux, bowel obstruction, anastomotic ulcers, anastomotic stenosis, internal hernia, chronic gastritis, esophagitis, iron deficiency anemia)

    Time frame: During the month following surgery (for early complications) and from one month to 12 months postoperatively (for late complications)]

  5. Type and severity of early and late complications for each procedure

    Type and severity of early and late complications for each procedure, according to the Dindo-Clavien classification

    Time frame: During the month following surgery (for early complications) and from one month to 12 months postoperatively (for late complications)]

  6. Patient's quality of life score according to the Impact of Weight on Quality of Life (IWQOL) questionnaire

    The IWQOL questionnaire to be specifically assess the effects of obesity on health-related quality of life. The five identified scales are Physical Function, Self-Esteem, Sexual Life, Public Distress, and Work. The final 20-item IWQOL includes two primary domains: Physical (7 items) and Psychosocial (13 items)

    Time frame: Before surgery and at 12 after surgery

  7. Patient's quality of life score according to the Gastrointestinal Quality of Life Index (GIQLI) questionnaire adapted to bariatric surgery.

    GIQLI (gastrointestinal quality of life index) questionnaire. 36 questions, each containing 4 answers equating to a score ranging from 0 (least desirable answer) to 4 (most desirable answer). Total score range 0-144.

    Time frame: Before surgery and at 12 after surgery

  8. Change in glucose homeostasis

    glucose (mg/dl)

    Time frame: Before surgery and at 3, 6 and 12 months after surgery

  9. Change in HbA1c

    Changes in HbA1c(%) were assessed before and after surgery

    Time frame: Before surgery and at 3, 6 and 12 months after surgery

  10. Change in fasting glycemia

    Changes in fasting blood glucose levels (mmol/L)

    Time frame: Before surgery and at 3, 6 and 12 months after surgery

  11. changes in fasting insulinemia

    Changes in fasting insulinemia in microunits/mL

    Time frame: Before surgery and at 3, 6 and 12 months after surgery

  12. change in fasting c-peptide

    Changes in C-peptide(ng/ml) were assessed before and after the intervention.

    Time frame: Before surgery and at 3, 6 and 12 months after surgery

  13. Number of antidiabetic treatments

    Metabolic profile of glucose homeostasis assessment according to antidiabetic treatments, HbA1c level, fasting glycemia, fasting insulinemia fasting c-peptide

    Time frame: Before surgery and at 3, 6 and 12 months after surgery

  14. Changes in blood lipids profile

    Changes in blood lipids profile (LDL, HDL and triglyceride concentrations) according to anitilipidemic treatments

    Time frame: Before surgery and at 1, 3, 6 and 12 months after surgery

  15. change in vitamins status assessment

    vitamines profil (vitamin B1, B9, B12, and D concentration) before and 12 and 24 months after surgery

    Time frame: Before surgery and at 1, 3, 6 and 12 months after surgery

  16. change in prealbumin levels

    Lower levels of prealbumin are associated with malnutrition.

    Time frame: Before surgery and at 1, 3, 6 and 12 months after surgery

07

Study locations

4 of 4 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2019 (actual). Primary completion is estimated for Jun 2026, 84 months after the start.

Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 84 months is above that.

Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 26, 2018
First posted
Jan 30, 2019
StartActual
Jun 16, 2019
Primary completionEst.
Jun 2026
CompletionEst.
Jun 2026
Last update
Dec 23, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03821636
Collaborators
Ministry of Health, France
Responsible party
Sponsor
First posted
Jan 30, 2019
Start date
Jun 16, 2019
Primary completion
Jun 2026 (estimated)
Completion
Jun 2026 (estimated)
Last update
Dec 23, 2025

Study contacts

Grégory BAUD, MD
Contact
gregory.baud@chru-lille.fr
3.20.44.42.73 ext. +33
Grégory BAUD, MD
principal investigator · University Hospital, Lille

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion